SCHEMBL17154387

SCHEMBL17154387

Nc1ccc(Nc2c3ccccc3nc3ccccc23)c(N)c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 7/20 0.71
TOP2B Q02880 4/20 0.49
TOP2A P11388 3/20 0.49
KMT2A Q03164 6/20 0.49
MEN1 O00255 4/20 0.49
POLB P06746 2/20 0.49
GAA P10253 1/20 0.49
SMN1; SMN2 Q16637 3/20 0.47
RAB9A P51151 3/20 0.47
MAPT P10636 2/20 0.47
MAPK1 P28482 1/20 0.47
RAD52 P43351 3/20 0.45
GFER P55789 2/20 0.45
ATM Q13315 1/20 0.45
GLA P06280 3/20 0.44
CHRM1 P11229 2/20 0.44
CASP1 P29466 2/20 0.44
CASP7 P55210 2/20 0.44
KCNH2 Q12809 2/20 0.44
HSD17B10 Q99714 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17154467 0.84 KDM1A (0.58) KDM1ATOP2BTOP2AKMT2AMEN1
SCHEMBL4906421 0.81 KDM1A (0.58) KDM1ATOP2BTOP2AKMT2AMEN1
SCHEMBL17154445 0.81 KMT2A (0.54) KDM1ATOP2BTOP2AKMT2AMEN1
SCHEMBL13529531 0.81 POLB (0.69) KDM1ATOP2BTOP2AKMT2AMEN1
Hydrochloric Acid SCHEMBL6883145 0.80 KDM1A (0.56) KDM1ATOP2BTOP2AKMT2AMEN1
SCHEMBL17423377 0.79 KDM1A (0.64) KDM1ATOP2BTOP2AKMT2AMEN1
SCHEMBL4928153 0.78 KMT2A (0.73) KDM1ATOP2BTOP2AKMT2AMEN1
SCHEMBL17154394 0.76 KDM1A (0.84) KDM1ATOP2BTOP2AKMT2AMEN1
SCHEMBL17154450 0.76 KDM1A (1.00) KDM1ATOP2BTOP2AKMT2AMEN1
SCHEMBL17154397 0.75 KDM1A (0.68) KDM1ATOP2BTOP2AKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10183912-B2 HDMX inhibitors and their use for cancer treatment MiRx Pharmaceuticals, LLC (US) 2019-01-22 US disclosed
US-20170022166-A1 NOVEL HDMX INHIBITORS AND THEIR USE FOR CANCER TREATMENT MIRX PHARMACEUTICALS LLC (US) 2017-01-26 US disclosed
US-20170022166-A1 NOVEL HDMX INHIBITORS AND THEIR USE FOR CANCER TREATMENT MIRX PHARMACEUTICALS LLC (US) 2017-01-26 US disclosed
WO-2015153535-A1 NOVEL HDMX INHIBITORS AND THEIR USE FOR CANCER TREATMENT MiRx Pharmaceuticals, LLC (US) 2015-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170022166-A1 NOVEL HDMX INHIBITORS AND THEIR USE FOR CANCER TREATMENT TP53, DDX3X, API5 KDM1A 702/4885TOP2B 1788/4885TOP2A 1603/4885
US-10183912-B2 HDMX inhibitors and their use for cancer treatment TP53, MDM4, MDM2 KDM1A 650/4885TOP2B 1738/4885TOP2A 1618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.